Cancer immunotherapy via dendritic cells
K Palucka, J Banchereau - Nature Reviews Cancer, 2012 - nature.com
Cancer immunotherapy attempts to harness the power and specificity of the immune system
to treat tumours. The molecular identification of human cancer-specific antigens has allowed …
to treat tumours. The molecular identification of human cancer-specific antigens has allowed …
Trial watch: Dendritic cell-based interventions for cancer therapy
Dendritic cells (DCs) occupy a central position in the immune system, orchestrating a wide
repertoire of responses that span from the development of self-tolerance to the elicitation of …
repertoire of responses that span from the development of self-tolerance to the elicitation of …
Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric …
T Masuzawa, Y Fujiwara, K Okada… - International …, 2012 - spandidos-publications.com
The aim of this study was to evaluate the safety and efficacy of vaccination with human
leukocyte antigen (HLA)-A24-restricted human vascular endothelial growth factor receptor 1 …
leukocyte antigen (HLA)-A24-restricted human vascular endothelial growth factor receptor 1 …
Targeting the epidermal growth factor receptor in solid tumor malignancies
MK Nedergaard, CJ Hedegaard, HS Poulsen - BioDrugs, 2012 - Springer
The epidermal growth factor receptor (EGFR) is over-expressed, as well as mutated, in many
types of cancers. In particular, the EGFR variant type III mutant (EGFRvIII) has attracted much …
types of cancers. In particular, the EGFR variant type III mutant (EGFRvIII) has attracted much …
Dendritic cell therapy for Type 1 diabetes suppression
N Giannoukakis, M Trucco - Immunotherapy, 2012 - Taylor & Francis
While dendritic cell-based therapy is a clinical reality for human malignancies, until now,
some conceptual concerns have served to delay its consideration to treat human …
some conceptual concerns have served to delay its consideration to treat human …
Extracorporeal removal of microvesicular particles
T Ichim, RH Tullis - US Patent 8,288,172, 2012 - Google Patents
Caby et al.,“Exosomal-like vesicles are present in human blood plasma, Int Immunol (2005)
17: 879-887. Clayton et al.,“Exosomes and the MICA-NKG2D system in cancer', Blood Cells …
17: 879-887. Clayton et al.,“Exosomes and the MICA-NKG2D system in cancer', Blood Cells …
附子多糖诱导肝癌患者外周血树突状细胞分化成熟的实验研究
高林林， 曾升平， 潘力弢 - 中国肿瘤临床, 2012 - cjco.cn
中国肿瘤临床附子多糖诱导肝癌患者外周血树突状细胞分化成熟的实验研究 Page 1 中国肿瘤
临床 2012年第39卷第13期 附子多糖诱导肝癌患者外周血树突状细胞分化 成熟的实验研究 高林 …
临床 2012年第39卷第13期 附子多糖诱导肝癌患者外周血树突状细胞分化 成熟的实验研究 高林 …
[PDF][PDF] Enhancing graft-versus-leukemia after transplant: the rise of anti-cancer vaccines
A Brusic, CJ Wu - Front Biosci, 2012 - Citeseer
[Frontiers in Bioscience 17, 635-655, January 1, 2012] 635 Enhancing graft-versus-leukemia
after transplant: the rise of anti-ca Page 1 [Frontiers in Bioscience 17, 635-655, January 1, 2012] …
after transplant: the rise of anti-ca Page 1 [Frontiers in Bioscience 17, 635-655, January 1, 2012] …
Оптимизация метода получения дендритных клеток из гемопоэтических стволовых клеток костного мозга для иммунотерапии пациентов с туберкулезом
АЕ Гончаров, ЛП Титов, ИВ Романова… - Доклады …, 2012 - elibrary.ru
В результате проведения исследований для генерации дендритных клеток подобрана
оптимальная комбинация цитокинов, включающая ГМ-КСФ, ИЛ-4 и ФНО-а. Дендритные …
оптимальная комбинация цитокинов, включающая ГМ-КСФ, ИЛ-4 и ФНО-а. Дендритные …
Immunotherapy with tumor vaccines for the treatment of malignant gliomas
D Ajay, L Sanchez-Perez, BD Choi… - Current Drug …, 2012 - ingentaconnect.com
With an average life expectancy of 14 months, Glioblastoma multiforme (GBM), is the most
aggressive primary brain tumor. Our growing understanding of the immune system and its …
aggressive primary brain tumor. Our growing understanding of the immune system and its …